Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine

Journal of Clinical Psychiatry

Volumn 69, Issue 1, 2008, Pages 54-59

  Lin, Ching Hua ^a   Lin, Keng Shin ^a   Lin, Chang Yi ^a   Chen, Ming Chao ^a   Lane, Hsien Yuan ^b,c,d  

^a Kaohisung Kai Suan Psychiatric Hospital   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PERSONALITY DISORDER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOSIS; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

EID: 39549096007     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0108     Document Type: Article

References (52)

1. Kessler, RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8-19
2. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. Arch Gen Psychiatry 1992;49:809-816
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
4. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-406
5. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther 2002;24:1194-1200
6. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16
7. Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther 2003;25:2138-2154
8. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001:178:234-241
9. Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine, and placebo. Int Clin Psychopharmacol 2005;20:233-238
10. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
11. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-1174
12. Labbate LA, Doyle MD. Recidivism in major depressive disorder. Psychother Psychosom 1997;66:145-149
13. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-861
14. Daniels BA, Kirkby KC, Hay DA, et al. Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder, and depression. Aust N Z J Psychiatry 1998;32:281-286
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
16. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
17. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157:1873-1875
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
19. Ananth J. Treatment-resistant depression. Psychother Psychosom 1998;67:61-70
20. Robertson MM, Trimble MR. Major tranquillisers used as antidepressants: a review. J Affect Disord 1982;4:173-193
21. Thase ME. What role do atypical antipsychotic drugs have in treatmentresistant depression? J Clin Psychiatry 2002;63:95-103
22. Klein DN, Schatzberg AF, McCullough JP, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 1999;55:149-157
23. Zisook S, Rush AJ, Albala Ari, et al. Factors that differentiate early vs later onset of major depression disorder. Psychiatry Res 2004;129:127-140
24. Russo J, Roy-Byrne P, Jaffe C, et al. Psychiatric status, quality of life, and level of care as predictors of outcomes of acute inpatient treatment. Psychiatr Serv 1997;48:1427-1434
25. Swett C. Symptom severity and number of previous psychiatric admissions as predictors of readmission. Psychiatr Serv 1995;46:482-485
26. Posternak MA, Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J Clin Psychiatry 2005;66:705-707
27. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71
28. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-28
29. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998;59:352-357
30. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-143
31. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181
32. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000;15:29-34
33. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998;51:237-254
34. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509
35. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 1998;59(suppl 18):23-29
36. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999;60:36-40
37. Lane HY, Chiu WC, Chou JCY, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61:209-214
38. Lane HY, Deng HC, Huang SM, et al. Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clin Pharmacol Ther 1996;60:696-698
39. Liao SC, Lee MB, Wu CH, et al. A single-blind and randomized trial of venlafaxine and fluoxetine for the treatment of major depression. Formosan J Med 2003;7:48-59
40. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995;152:379-384
41. Daniels BA, Kirkby KC, Hay DA, et al. Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder, and depression. Aust N Z J Psychiatry 1998;32:281-286
42. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57:53-60
43. Bernardo AC, Forchuk C. Factors associated with readmission to a psychiatric facility. Psychiatr Serv 2001;52:1100-1102
44. Uchida H, Takeuchi H, Suzuki T, et al. Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. J Clin Psychopharmacol 2005;25:545-551
45. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-259
46. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
47. Conley RR, Love RC, Kelly DL, et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-868
48. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-269
49. Patel NC, Dorson PG, Edward N, et al. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002;53:891-893
50. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry 2004;161:1285-1289
51. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-466
52. Keller MB. The difficult depressed patient in perspective. J Clin Psychiatry 1993;54(suppl):4-8